Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection. (Q39468421)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21945962%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21945962%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21945962%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Adam C Finnefrock

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21945962%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

Fengsheng Li

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21945962%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Daniel C Freed

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21945962%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Aimin Tang

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21945962%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Shannon N Grimes

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21945962%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Danilo R Casimiro

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21945962%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Tong-Ming Fu

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21945962%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

language of work or name

English

0 references

publication date

22 September 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21945962%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

number of pages

6

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21945962%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21945962%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

9075-9080

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21945962%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

48

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21945962%20AND%20SRC:MED&resulttype=core&format=json

The outcome of congenital cytomegalovirus infection in relation to maternal antibody status

13 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.056

Cytomegalovirus seroconversion rates and risk factors: implications for congenital CMV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.056

Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.056

Maternal immunity and prevention of congenital cytomegalovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.056

Passive Immunization during Pregnancy for Congenital Cytomegalovirus Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.056

Vaccine prevention of maternal cytomegalovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.056

Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.056

Human cytomegalovirus uses two distinct pathways to enter retinal pigmented epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.056

Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.056

Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.056

Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.056

Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.056

Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.056

Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.056

Rescue of human cytomegalovirus strain AD169 tropism for both leukocytes and human endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.056

Human cytomegalovirus replicates abortively in polymorphonuclear leukocytes after transfer from infected endothelial cells via transient microfusion events.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.056

Preservation of natural endothelial cytopathogenicity of cytomegalovirus by propagation in endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.056

Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.056

Pathogenesis of human cytomegalovirus infection and cellular targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.056

High-throughput sequence analysis of variants of human cytomegalovirus strains Towne and AD169.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.056

Human cytomegalovirus UL131A, UL130 and UL128 genes are highly conserved among field isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.056

Cytomegalovirus infection and the risk of mortality and frailty in older women: a prospective observational cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.056

Cytomegalovirus antibody level and mortality among community-dwelling older adults with stable cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.056

Large-scale testing of human serum to determine cytomegalovirus neutralising antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.056

Assessment of the presence of cytomegalovirus-neutralizing antibody by a plaque-reduction assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.056

Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.056

A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.056

Safety and immunogenicity of the Towne strain cytomegalovirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.056

Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.056

Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.056

Development of human cytomegalovirus-specific T cell immunity during primary infection of pregnant women and its correlation with virus transmission to the fetus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.056